Biomarkers

Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study

Evaluating Plasma p-tau217 as an Endpoint for Alzheimer Disease Clinical Trials

Low-dose CT for MRI-free quantification of tau PET in Alzheimer's disease: a multicentre, cross-sectional, comparison study

Tau PET quantification typically requires structural MRI for reference-region definition, normalisation, and segmentation, which imposes a logistical and operational burden. In …

In vivo-measured Lewy body pathology is associated with neuropsychiatric symptoms across the Alzheimer’s disease continuum

CSF total tau as a proxy of synaptic degeneration

Cerebrospinal fluid (CSF) total tau (t-tau) is considered a biomarker of neuronal degeneration alongside brain atrophy and fluid neurofilament light chain protein (NfL) in …

Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer's disease

BACKGROUND: Clinical trials have recently incorporated plasma glial fibrillary acidic protein (GFAP) as an exploratory endpoint. To include plasma GFAP as a secondary endpoint, it …

Glial reactivity correlates with synaptic dysfunction across aging and Alzheimer's disease

Previous studies suggest glial and neuronal changes may trigger synaptic dysfunction in Alzheimer's disease (AD), but the link between their markers and synaptic abnormalities in …

Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease

INTRODUCTION: Cognitively unimpaired (CU) amyloid beta (Aβ)+ individuals with elevated plasma glial fibrillary acidic protein (GFAP) have an increased risk of Alzheimer's disease …

Amyloid beta and tau are associated with the dual effect of neuroinflammation on neurodegeneration

INTRODUCTION Current literature presents conflicting results regarding the impact of neuroinflammation on Alzheimer's disease (AD)-related neurodegeneration. While some studies …